158 related articles for article (PubMed ID: 16712612)
1. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.
Traum AZ; Rodig NM; Pilichowska ME; Somers MJ
Pediatr Transplant; 2006 Jun; 10(4):505-12. PubMed ID: 16712612
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports.
Arita H; Izumoto S; Kinoshita M; Okita Y; Hashimoto N; Fujita T; Ichimaru N; Takahara S; Yoshimine T
Neurol Med Chir (Tokyo); 2010; 50(12):1079-83. PubMed ID: 21206182
[TBL] [Abstract][Full Text] [Related]
3. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
4. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.
Twombley K; Pokala H; Ardura MI; Harker-Murray P; Johnson-Welch SF; Weinberg A; Seikaly M
Pediatr Transplant; 2012 Sep; 16(6):E201-9. PubMed ID: 22646132
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of monomorphic primary central nervous system post-transplantation lymphoproliferative disorder 5 years after kidney transplantation.
Yaginuma T; Yamamoto H; Mitome J; Tanno Y; Yamamoto I; Kobayashi A; Mafune A; Hayakawa H; Yokoyama K; Mori R; Ohashi H; Kaito N; Joki T; Miki J; Yamada H; Furuta N; Matsushima S; Fukuda T; Hosoya T
Transpl Infect Dis; 2012 Oct; 14(5):E102-6. PubMed ID: 22931101
[TBL] [Abstract][Full Text] [Related]
6. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.
Patrick A; Wee A; Hedderman A; Wilson D; Weiss J; Govani M
J Neurooncol; 2011 Jul; 103(3):739-43. PubMed ID: 20872273
[TBL] [Abstract][Full Text] [Related]
7. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
[TBL] [Abstract][Full Text] [Related]
8. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
[TBL] [Abstract][Full Text] [Related]
10. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
[TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
12. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.
Kanzelmeyer NK; Maecker-Kolhoff B; Zierhut H; Lerch C; Verboom M; Haffner D; Pape L
Transpl Int; 2018 Apr; 31(4):367-376. PubMed ID: 28906028
[TBL] [Abstract][Full Text] [Related]
13. Posttransplantation lymphoproliferative disorder: changing manifestations of disease in a renal transplant population.
Miller WT; Siegel SG; Montone KT
Crit Rev Diagn Imaging; 1997 Dec; 38(6):569-85. PubMed ID: 9442979
[TBL] [Abstract][Full Text] [Related]
14. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.
Ganzemueller J; Hartmann B; Keller F; Stracke S
Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981
[TBL] [Abstract][Full Text] [Related]
15. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
16. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
17. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience.
Nakanishi C; Kawagishi N; Sekiguchi S; Akamatsu Y; Sato K; Miyagi S; Takeda I; Fukushima D; Kobayashi Y; Ishida K; Niizuma H; Tsuchiya S; Wada M; Nio M; Satomi S
Surg Today; 2012 Aug; 42(8):741-51. PubMed ID: 22278621
[TBL] [Abstract][Full Text] [Related]
19. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
[TBL] [Abstract][Full Text] [Related]
20. Pathology of central nervous system posttransplant lymphoproliferative disorders: lessons from pediatric autopsies.
Gheorghe G; Radu O; Milanovich S; Hamilton RL; Jaffe R; Southern JF; Ozolek JA
Pediatr Dev Pathol; 2013; 16(2):67-73. PubMed ID: 23286282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]